Headquartered in Ålesund, Pharma Nordic develops and markets self-care pharmaceuticals such as the Proponent nasal spray and the Bentrio allergy blocker. The company focuses on health products that can be purchased without prescription, targeting consumers throughout the Nordic countries. Pharma Nordic is now gearing up for the EU’s forthcoming AI Act, which will impose strict documentation and risk-assessment requirements on high-risk AI systems in healthcare starting August 2026. To meet these demands, the firm has brought artificial-intelligence expertise onto its shareholder roster. Its new partner, ARTI Consult, will help build compliant AI decision-support and regulatory documentation frameworks. The move is positioned as a competitive advantage, enabling the company to adopt AI responsibly while scaling operations. A recent NOK 15 million capital injection will finance this regulatory readiness and support further regional expansion.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2026